| __timestamp | CymaBay Therapeutics, Inc. | Rhythm Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 8185000 | 1213000 |
| Thursday, January 1, 2015 | 8871000 | 3425000 |
| Friday, January 1, 2016 | 9645000 | 6311000 |
| Sunday, January 1, 2017 | 12387000 | 9518000 |
| Monday, January 1, 2018 | 14381000 | 28080000 |
| Tuesday, January 1, 2019 | 19238000 | 36550000 |
| Wednesday, January 1, 2020 | 17425000 | 46125000 |
| Friday, January 1, 2021 | 23040000 | 68486000 |
| Saturday, January 1, 2022 | 25116000 | 92032000 |
| Sunday, January 1, 2023 | 51953000 | 117532000 |
Data in motion
In the competitive world of biotechnology, managing operational costs is crucial for success. This chart compares the Selling, General, and Administrative (SG&A) expenses of CymaBay Therapeutics, Inc. and Rhythm Pharmaceuticals, Inc. from 2014 to 2023. Over this period, Rhythm Pharmaceuticals has consistently outpaced CymaBay in SG&A spending, with a staggering 1,175% increase from 2014 to 2023. In contrast, CymaBay's expenses grew by approximately 535% during the same period. Notably, 2023 marked a significant spike for both companies, with CymaBay's expenses reaching 52 million and Rhythm's soaring to 118 million. This trend highlights the aggressive expansion and operational scaling within the biotech sector. As these companies continue to innovate, understanding their financial strategies offers valuable insights into their market positioning and future growth potential.
SG&A Efficiency Analysis: Comparing Merck & Co., Inc. and CymaBay Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Bristol-Myers Squibb Company and CymaBay Therapeutics, Inc.
Gilead Sciences, Inc. vs Rhythm Pharmaceuticals, Inc.: SG&A Expense Trends
Biogen Inc. and Rhythm Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: United Therapeutics Corporation vs Rhythm Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Insmed Incorporated vs CymaBay Therapeutics, Inc.
Halozyme Therapeutics, Inc. vs CymaBay Therapeutics, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: Cytokinetics, Incorporated vs Rhythm Pharmaceuticals, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for ADMA Biologics, Inc. and Rhythm Pharmaceuticals, Inc.
CymaBay Therapeutics, Inc. vs ACADIA Pharmaceuticals Inc.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Rhythm Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc.
Rhythm Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.: SG&A Spending Patterns Compared